Skip to content
Bristol Myers Squibb
-
Bristol Myers Squibb bets US$15.2B on Hengrui partnership to accelerate global drug pipeline
Hengrui will oversee the initial human clinical studies for the immunology assets licensed from BMS, a move intended to speed up proof-of-concept data generation.
-
OXB expands its partnership with Bristol Myers Squibb to launch commercial manufacturing of CAR-T therapy components
The company plans to utilize two key facilities for this production: its Oxford, United Kingdom site and its Durham, North Carolina location.
-
Bristol Myers Squibb strengthens oncology pipeline with USD850M Janux Therapeutics partnership
BMS will pay up to USD850 million, structured as USD50 million in upfront and near-term payments combined with USD800 million in regulatory, development, and milestone-based payouts.